APO Research
Talk to an analyst

APO RESEARCH · REPORT

Retinal Disorders Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Retinal Disorders Therapy Market Outlook and Growth Opportunities 2026

19 December 2025201 pages

Choose your research edition.

Industry ResearchRetinal Disorders Therapy Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Retinal Disorders Therapy Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Retinal Disorders Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Retinal Disorders Therapy Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Retinal Disorders Therapy Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Retinal Disorders Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Retinal Disorders Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Retinal Disorders Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Retinal Disorders Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Retinal Disorders Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Retinal Disorders Therapy market include ALLERGAN, Alimera Sciences, Bausch & Lomb, Bristol-Myers Squibb, Genentech, Genzyme, Janssen Biotech, OCULAR THERAPEUTIX and Swedish Orphan Biovitrum, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Retinal Disorders Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Retinal Disorders Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Retinal Disorders Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Retinal Disorders Therapy market.

Retinal Disorders Therapy Segment by Company

ALLERGAN

Alimera Sciences

Bausch & Lomb

Bristol-Myers Squibb

Genentech

Genzyme

Janssen Biotech

OCULAR THERAPEUTIX

Swedish Orphan Biovitrum

UCBCares

AbbVie

Eyebright Medical

Aier Eye Hospital

Alcon Holdings, Inc.

Huaxia Eye Hospital

Kanghong Pharmaceutical

Roche

Xingqi Pharmaceutical

Retinal Disorders Therapy Segment by Type

Ocular Inflammatory Disease (Uveitis)

Diabetic Retinopathy

Age Related Macular Degeneration

Macular Hole

Retinal Disorders Therapy Segment by Application

Hospitals

Clinics

Others

Retinal Disorders Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Retinal Disorders Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Retinal Disorders Therapy key companies, revenue, market share, and recent developments.

3. To split the Retinal Disorders Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Retinal Disorders Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Retinal Disorders Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Retinal Disorders Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Disorders Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Retinal Disorders Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Disorders Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Retinal Disorders Therapy industry.

Chapter 3: Detailed analysis of Retinal Disorders Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Retinal Disorders Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Retinal Disorders Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Retinal Disorders Therapy Industry Trends Table 2. Retinal Disorders Therapy Industry Drivers Table 3. Retinal Disorders Therapy Industry Opportunities and Challenges Table 4. Retinal Disorders Therapy Industry Restraints Table 5. Global Retinal Disorders Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Retinal Disorders Therapy Revenue Share by Company (2021-2026) Table 7. Global Retinal Disorders Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Retinal Disorders Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Retinal Disorders Therapy Company, Product Type & Application Table 10. Global Retinal Disorders Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Retinal Disorders Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ocular Inflammatory Disease (Uveitis) Table 15. Significant Companies of Diabetic Retinopathy Table 16. Significant Companies of Age Related Macular Degeneration Table 17. Significant Companies of Macular Hole Table 18. Global Retinal Disorders Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Retinal Disorders Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Retinal Disorders Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Retinal Disorders Therapy Sales Value Share by Type (2021-2026) Table 22. Global Retinal Disorders Therapy Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Clinics Table 25. Significant Companies of Others Table 26. Global Retinal Disorders Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Retinal Disorders Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Retinal Disorders Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Retinal Disorders Therapy Sales Value Share by Application (2021-2026) Table 30. Global Retinal Disorders Therapy Sales Value Share by Application (2027-2032) Table 31. Global Retinal Disorders Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Retinal Disorders Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Retinal Disorders Therapy Sales Value Share by Region (2021-2026) Table 34. Global Retinal Disorders Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Retinal Disorders Therapy Sales Value Share by Region (2027-2032) Table 36. Global Retinal Disorders Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Retinal Disorders Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Retinal Disorders Therapy Sales Value Market Share by Country (2021-2026) Table 39. Global Retinal Disorders Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Retinal Disorders Therapy Sales Value Market Share by Country (2027-2032) Table 41. ALLERGAN Company Information Table 42. ALLERGAN Business Overview Table 43. ALLERGAN Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. ALLERGAN Retinal Disorders Therapy Product Portfolio Table 45. ALLERGAN Recent Development Table 46. Alimera Sciences Company Information Table 47. Alimera Sciences Business Overview Table 48. Alimera Sciences Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Alimera Sciences Retinal Disorders Therapy Product Portfolio Table 50. Alimera Sciences Recent Development Table 51. Bausch & Lomb Company Information Table 52. Bausch & Lomb Business Overview Table 53. Bausch & Lomb Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Bausch & Lomb Retinal Disorders Therapy Product Portfolio Table 55. Bausch & Lomb Recent Development Table 56. Bristol-Myers Squibb Company Information Table 57. Bristol-Myers Squibb Business Overview Table 58. Bristol-Myers Squibb Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Bristol-Myers Squibb Retinal Disorders Therapy Product Portfolio Table 60. Bristol-Myers Squibb Recent Development Table 61. Genentech Company Information Table 62. Genentech Business Overview Table 63. Genentech Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Genentech Retinal Disorders Therapy Product Portfolio Table 65. Genentech Recent Development Table 66. Genzyme Company Information Table 67. Genzyme Business Overview Table 68. Genzyme Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Genzyme Retinal Disorders Therapy Product Portfolio Table 70. Genzyme Recent Development Table 71. Janssen Biotech Company Information Table 72. Janssen Biotech Business Overview Table 73. Janssen Biotech Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Janssen Biotech Retinal Disorders Therapy Product Portfolio Table 75. Janssen Biotech Recent Development Table 76. OCULAR THERAPEUTIX Company Information Table 77. OCULAR THERAPEUTIX Business Overview Table 78. OCULAR THERAPEUTIX Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. OCULAR THERAPEUTIX Retinal Disorders Therapy Product Portfolio Table 80. OCULAR THERAPEUTIX Recent Development Table 81. Swedish Orphan Biovitrum Company Information Table 82. Swedish Orphan Biovitrum Business Overview Table 83. Swedish Orphan Biovitrum Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Swedish Orphan Biovitrum Retinal Disorders Therapy Product Portfolio Table 85. Swedish Orphan Biovitrum Recent Development Table 86. UCBCares Company Information Table 87. UCBCares Business Overview Table 88. UCBCares Retinal Disorders Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. UCBCares Retinal Disorders Therapy Product Portfolio Table 90. UCBCares Recent Development Table 91. AbbVie Company Information Table 92. AbbVie Business Overview Table 93. AbbVie Retinal Disorders Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AbbVie Retinal Disorders Therapy Product Portfolio Table 95. AbbVie Recent Development Table 96. Eyebright Medical Company Information Table 97. Eyebright Medical Business Overview Table 98. Eyebright Medical Retinal Disorders Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Eyebright Medical Retinal Disorders Therapy Product Portfolio Table 100. Eyebright Medical Recent Development Table 101. Aier Eye Hospital Company Information Table 102. Aier Eye Hospital Business Overview Table 103. Aier Eye Hospital Retinal Disorders Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Aier Eye Hospital Retinal Disorders Therapy Product Portfolio Table 105. Aier Eye Hospital Recent Development Table 106. Alcon Holdings, Inc. Company Information Table 107. Alcon Holdings, Inc. Business Overview Table 108. Alcon Holdings, Inc. Retinal Disorders Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Alcon Holdings, Inc. Retinal Disorders Therapy Product Portfolio Table 110. Alcon Holdings, Inc. Recent Development Table 111. Huaxia Eye Hospital Company Information Table 112. Huaxia Eye Hospital Business Overview Table 113. Huaxia Eye Hospital Retinal Disorders Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Huaxia Eye Hospital Retinal Disorders Therapy Product Portfolio Table 115. Huaxia Eye Hospital Recent Development Table 116. Kanghong Pharmaceutical Company Information Table 117. Kanghong Pharmaceutical Business Overview Table 118. Kanghong Pharmaceutical Retinal Disorders Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Kanghong Pharmaceutical Retinal Disorders Therapy Product Portfolio Table 120. Kanghong Pharmaceutical Recent Development Table 121. Roche Company Information Table 122. Roche Business Overview Table 123. Roche Retinal Disorders Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Roche Retinal Disorders Therapy Product Portfolio Table 125. Roche Recent Development Table 126. Xingqi Pharmaceutical Company Information Table 127. Xingqi Pharmaceutical Business Overview Table 128. Xingqi Pharmaceutical Retinal Disorders Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Xingqi Pharmaceutical Retinal Disorders Therapy Product Portfolio Table 130. Xingqi Pharmaceutical Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Retinal Disorders Therapy Product Image Figure 2. Global Retinal Disorders Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Retinal Disorders Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Retinal Disorders Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ocular Inflammatory Disease (Uveitis) Image Figure 8. Diabetic Retinopathy Image Figure 9. Age Related Macular Degeneration Image Figure 10. Macular Hole Image Figure 11. Global Retinal Disorders Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Retinal Disorders Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Retinal Disorders Therapy Sales Value Share by Type (2021-2032) Figure 14. Hospitals Image Figure 15. Clinics Image Figure 16. Others Image Figure 17. Global Retinal Disorders Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Retinal Disorders Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Retinal Disorders Therapy Sales Value Share by Application (2021-2032) Figure 20. Global Retinal Disorders Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Retinal Disorders Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Retinal Disorders Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. North America Retinal Disorders Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Retinal Disorders Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Retinal Disorders Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Retinal Disorders Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Retinal Disorders Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Retinal Disorders Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. South America Retinal Disorders Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Retinal Disorders Therapy Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Retinal Disorders Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Retinal Disorders Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Ocular Inflammatory Disease (Uveitis)
  • Diabetic Retinopathy
  • Age Related Macular Degeneration
  • Macular Hole
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • ALLERGAN
  • Alimera Sciences
  • Bausch & Lomb
  • Bristol-Myers Squibb
  • Genentech
  • Genzyme
  • Janssen Biotech
  • OCULAR THERAPEUTIX
  • Swedish Orphan Biovitrum
  • UCBCares
  • AbbVie
  • Eyebright Medical
  • Aier Eye Hospital
  • Alcon Holdings, Inc.
  • Huaxia Eye Hospital
  • Kanghong Pharmaceutical
  • Roche
  • Xingqi Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Retinal Disorders Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Retinal Disorders Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Retinal Disorders Therapy Market Dynamics
  1. 2.1 Retinal Disorders Therapy Industry Trends
  2. 2.2 Retinal Disorders Therapy Industry Drivers
  3. 2.3 Retinal Disorders Therapy Industry Opportunities and Challenges
  4. 2.4 Retinal Disorders Therapy Industry Restraints
3 Retinal Disorders Therapy Market by Company
  1. 3.1 Global Retinal Disorders Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Retinal Disorders Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Retinal Disorders Therapy Company Ranking (2024-2026)
  4. 3.4 Global Retinal Disorders Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Retinal Disorders Therapy Company Product Type and Application
  6. 3.6 Global Retinal Disorders Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Retinal Disorders Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Retinal Disorders Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Retinal Disorders Therapy Market by Type
  1. 4.1 Retinal Disorders Therapy Type Introduction
  2. 4.1.1 Ocular Inflammatory Disease (Uveitis)
  3. 4.1.2 Diabetic Retinopathy
  4. 4.1.3 Age Related Macular Degeneration
  5. 4.1.4 Macular Hole
  6. 4.2 Global Retinal Disorders Therapy Sales Value by Type
  7. 4.2.1 Global Retinal Disorders Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Retinal Disorders Therapy Sales Value by Type (2021-2032)
  9. 4.2.3 Global Retinal Disorders Therapy Sales Value Share by Type (2021-2032)
5 Retinal Disorders Therapy Market by Application
  1. 5.1 Retinal Disorders Therapy Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Retinal Disorders Therapy Sales Value by Application
  6. 5.2.1 Global Retinal Disorders Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Retinal Disorders Therapy Sales Value by Application (2021-2032)
  8. 5.2.3 Global Retinal Disorders Therapy Sales Value Share by Application (2021-2032)
6 Retinal Disorders Therapy Regional Value Analysis
  1. 6.1 Global Retinal Disorders Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Retinal Disorders Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Retinal Disorders Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Retinal Disorders Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Retinal Disorders Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Retinal Disorders Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Retinal Disorders Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Retinal Disorders Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Retinal Disorders Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Retinal Disorders Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Retinal Disorders Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Retinal Disorders Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Retinal Disorders Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Retinal Disorders Therapy Sales Value Share by Country, 2025 VS 2032
7 Retinal Disorders Therapy Country-level Value Analysis
  1. 7.1 Global Retinal Disorders Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Retinal Disorders Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Retinal Disorders Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Retinal Disorders Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Retinal Disorders Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Retinal Disorders Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Retinal Disorders Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ALLERGAN
  2. 8.1.1 ALLERGAN Company Information
  3. 8.1.2 ALLERGAN Business Overview
  4. 8.1.3 ALLERGAN Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ALLERGAN Retinal Disorders Therapy Product Portfolio
  6. 8.1.5 ALLERGAN Recent Developments
  7. 8.2 Alimera Sciences
  8. 8.2.1 Alimera Sciences Company Information
  9. 8.2.2 Alimera Sciences Business Overview
  10. 8.2.3 Alimera Sciences Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alimera Sciences Retinal Disorders Therapy Product Portfolio
  12. 8.2.5 Alimera Sciences Recent Developments
  13. 8.3 Bausch & Lomb
  14. 8.3.1 Bausch & Lomb Company Information
  15. 8.3.2 Bausch & Lomb Business Overview
  16. 8.3.3 Bausch & Lomb Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bausch & Lomb Retinal Disorders Therapy Product Portfolio
  18. 8.3.5 Bausch & Lomb Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Retinal Disorders Therapy Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Genentech Retinal Disorders Therapy Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Genzyme
  32. 8.6.1 Genzyme Company Information
  33. 8.6.2 Genzyme Business Overview
  34. 8.6.3 Genzyme Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genzyme Retinal Disorders Therapy Product Portfolio
  36. 8.6.5 Genzyme Recent Developments
  37. 8.7 Janssen Biotech
  38. 8.7.1 Janssen Biotech Company Information
  39. 8.7.2 Janssen Biotech Business Overview
  40. 8.7.3 Janssen Biotech Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Janssen Biotech Retinal Disorders Therapy Product Portfolio
  42. 8.7.5 Janssen Biotech Recent Developments
  43. 8.8 OCULAR THERAPEUTIX
  44. 8.8.1 OCULAR THERAPEUTIX Company Information
  45. 8.8.2 OCULAR THERAPEUTIX Business Overview
  46. 8.8.3 OCULAR THERAPEUTIX Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OCULAR THERAPEUTIX Retinal Disorders Therapy Product Portfolio
  48. 8.8.5 OCULAR THERAPEUTIX Recent Developments
  49. 8.9 Swedish Orphan Biovitrum
  50. 8.9.1 Swedish Orphan Biovitrum Company Information
  51. 8.9.2 Swedish Orphan Biovitrum Business Overview
  52. 8.9.3 Swedish Orphan Biovitrum Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Swedish Orphan Biovitrum Retinal Disorders Therapy Product Portfolio
  54. 8.9.5 Swedish Orphan Biovitrum Recent Developments
  55. 8.10 UCBCares
  56. 8.10.1 UCBCares Company Information
  57. 8.10.2 UCBCares Business Overview
  58. 8.10.3 UCBCares Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 UCBCares Retinal Disorders Therapy Product Portfolio
  60. 8.10.5 UCBCares Recent Developments
  61. 8.11 AbbVie
  62. 8.11.1 AbbVie Company Information
  63. 8.11.2 AbbVie Business Overview
  64. 8.11.3 AbbVie Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AbbVie Retinal Disorders Therapy Product Portfolio
  66. 8.11.5 AbbVie Recent Developments
  67. 8.12 Eyebright Medical
  68. 8.12.1 Eyebright Medical Company Information
  69. 8.12.2 Eyebright Medical Business Overview
  70. 8.12.3 Eyebright Medical Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eyebright Medical Retinal Disorders Therapy Product Portfolio
  72. 8.12.5 Eyebright Medical Recent Developments
  73. 8.13 Aier Eye Hospital
  74. 8.13.1 Aier Eye Hospital Company Information
  75. 8.13.2 Aier Eye Hospital Business Overview
  76. 8.13.3 Aier Eye Hospital Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Aier Eye Hospital Retinal Disorders Therapy Product Portfolio
  78. 8.13.5 Aier Eye Hospital Recent Developments
  79. 8.14 Alcon Holdings, Inc.
  80. 8.14.1 Alcon Holdings, Inc. Company Information
  81. 8.14.2 Alcon Holdings, Inc. Business Overview
  82. 8.14.3 Alcon Holdings, Inc. Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Alcon Holdings, Inc. Retinal Disorders Therapy Product Portfolio
  84. 8.14.5 Alcon Holdings, Inc. Recent Developments
  85. 8.15 Huaxia Eye Hospital
  86. 8.15.1 Huaxia Eye Hospital Company Information
  87. 8.15.2 Huaxia Eye Hospital Business Overview
  88. 8.15.3 Huaxia Eye Hospital Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Huaxia Eye Hospital Retinal Disorders Therapy Product Portfolio
  90. 8.15.5 Huaxia Eye Hospital Recent Developments
  91. 8.16 Kanghong Pharmaceutical
  92. 8.16.1 Kanghong Pharmaceutical Company Information
  93. 8.16.2 Kanghong Pharmaceutical Business Overview
  94. 8.16.3 Kanghong Pharmaceutical Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Kanghong Pharmaceutical Retinal Disorders Therapy Product Portfolio
  96. 8.16.5 Kanghong Pharmaceutical Recent Developments
  97. 8.17 Roche
  98. 8.17.1 Roche Company Information
  99. 8.17.2 Roche Business Overview
  100. 8.17.3 Roche Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Roche Retinal Disorders Therapy Product Portfolio
  102. 8.17.5 Roche Recent Developments
  103. 8.18 Xingqi Pharmaceutical
  104. 8.18.1 Xingqi Pharmaceutical Company Information
  105. 8.18.2 Xingqi Pharmaceutical Business Overview
  106. 8.18.3 Xingqi Pharmaceutical Retinal Disorders Therapy Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Xingqi Pharmaceutical Retinal Disorders Therapy Product Portfolio
  108. 8.18.5 Xingqi Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst